drugset / Trial / NCT05243862
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Phase 2
Active not recruiting
18 enrolled
Treos Bio Limited
Hoffmann-La Roche · collabMayo Clinic · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open label, phase II trial to determine the safety, tolerability, and immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018 vaccine and atezolizumab in participants with MSS CRC who have progressed on 2 or 3 prior regimens.
Timeline
- Start
- 2022-06-02
- Primary completion
- 2024-07-08
- Completion
- 2026-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | PolyPEPI1018 | Vaccine | 0.2 mg | Subcutaneous |